First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent (NOVA Trial)

Not Applicable

Completed

• Conditions: Ischemic Stroke
• Interventions: Device: Apollo Intracranial Stent System; Device: NOVA Intracranial Sirolimus Eluting Stent System

• Registration Number: NCT02578069
• Lead Sponsor: Sino Medical Sciences Technology Inc.

Brief Summary

Prospective, multi-center, randomized 1:1 single blind trial using NOVA sirolimus eluting stent versus Apollo bare metal stent conducted in approximately 15 interventional neurology centers in China. The study was sponsored by Sino Medical Sciences Technology Inc.

Detailed Description

The study will enroll 264 subjects overall in two groups (randomized 1:1). The study follow-up will occur at 1, 6 and 12 months post-stent implantation. All patients will undergo angiography assessment (DSA/CTA) at 12 months follow-up. Angiography assessment will be performed at baseline (pre- and post-procedure) and 12 months follow-up.

Study Timeline

• Study Start: 2015-04-27
• Study First Submitted: 2015-09-29
• Study First Submitted QC: 2015-10-14
• Study First Posted: 2015-10-16
• Status Verified: 2019-01
• Primary Completion: 2020-01
• Study Completion: 2020-01
• Last Update Submitted: 2021-10-11
• Last Update Posted: 2021-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 272

Inclusion Criteria

1. 18 to 75 years of age;

2. Primary or recurrent symptomatic intracranial arteriostenosis through the internal medicine treatment (i.e. stroke or transient ischemic attack within 90 days during the treatment with at least one anti-thrombotic drugs and vascular risk factor intervention e.g. hypertensors for hypertension and hypolipidemics for hyperlipidemia);

3. No transient ischemic attack (TIA) or ischemic stroke occurred within 2 weeks prior to stenting procedure;

4. ≥70% stenosis of intracranial responsible vessel under the DSA angiography (as judged through the WASID method);

5. Poor blood circulation in the side branch of responsible vessel area under the angiography within one week prior to stenting procedure:

   Score of blood circulation in the side branch under the DSA <3 or blood flow rate peak ≥200cm/s at the systolic phase under the transcranial doppler ultrasonic examination (TCD); or no apparent side branch compensation in the responsible vessel area under CTA or score of blood circulation in the side branch under the CTA <2;

6. The target lesion reference diameter must be visually estimated to be ≥2.0 mm in diameter, and lesion length must be <15 mm; no lesion observed in the distal vessel;

7. Atherosclerosis lesions;

8. mRS < 3;

9. Written informed consent.

Exclusion Criteria

1. >70% intracranial large-vessel stenosis beyond the responsible vessel;
2. >70% stenosis observed at the intracranial large-vessel distal to the responsible vessel or >70% stenosis observed at the intracranial/extracranial large-vessel proximal to the responsible vessel;
3. Acute ischemic stroke within 3 weeks;
4. Obstruction of perforating branch artery under the skull MRI;
5. Intracranial hemorrhage in the angiopathic area within 6 weeks;
6. Patient was treated by thrombolytic therapy within 24 hours;
7. Patients underwent surgery within 30 days or plan for surgery within 3 months post-stenting procedure;
8. Severe calcified lesions;
9. Patients have been treated by intracranial/extracranial stenting procedures prior to this study;
10. Nonatherosclerosis lesions;
11. Patients with potential sources for cardiac embolism;
12. Concomitant intracranial tumor, aneurysm or intracranial arteriovenous malformation;
13. Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, poly(lactic-co-glycolic acid) polymers, or poly(n-butyl methacrylate);
14. Hemoglobin <100g/L, platelet count <100,000 cells/mm3, International normalized ratio (INR) >1.5 (irreversible) or uncorrectable hemorrhagic factors;
15. Serious neural dysfunction due to the responsible angiopathy as the sequel of cerebral infarction (mRS≥3);
16. Known liver or renal insufficiency (ALT> 3x upper limit or AST > 3x upper limit, creatinine > 1.5x upper limit);
17. Life expectancy < 2 years;
18. Pregnant/lactating female patients;
19. Patients with cognitive impairment or mental diseases;
20. The patient participated in another investigational device or drug study within 3 months;
21. Inapplicable for intravascular stenting treatment as per investigators judgment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Apollo Intracranial Stent System	Apollo Intracranial stent system
Experimental	NOVA Intracranial Sirolimus Eluting Stent System	NOVA Intracranial sirolimus eluting stent system

Primary Outcome Measures

Name	Time	Method
In stent restenosis rate (> 50% restenosis)	12 months post-procedure	Angiography assessment at 12 months post-procedure

Secondary Outcome Measures

Name	Time	Method
Cerebral parenchyma hemorrhage, subarachnoid hemorrhage and intraventricular bleeding events	between 30 days and 1 year post-procedure
Death event	between 30 days and 1 year post-procedure
National Institutes of Health Stroke Scale (NIHSS) evaluation	at 1 and 12 months
Target vessel ischemic stroke event	between 30 days and 1 year post-procedure
Non-target vessels ischemic stroke event	between 30 days and 1 year post-procedure
Stroke and death events	within 30 days after stenting
Acute procedural success rate (stenosis < 30%)	1 year
modulate RANK score （mRS）evaluation	at 1 and 12 months
Montreal Cognitive Assessment (MoCA) evaluation	at 1 and 12 months
Recurrent ischemic stroke in the involved vascular area	between 30 days and 1 year post-procedure
Target vessel stroke or death events	within 30 days after stenting
Transient ischemic attack event	within 1 year post-procedure
EQ-5D score evaluation	at 12 months

Trial Locations

Locations (1)

Beijing Tiantan Hospital; 🇨🇳 Beijing, China